Targeted biologic therapy for asthma

Area of Science:

• Pulmonology and immunology
• Personalized medicine in respiratory diseases

Background:

• Asthma affects 300 million globally, historically treated with a uniform approach using corticosteroids and bronchodilators.
• Recent advances reveal asthma's heterogeneity, with distinct underlying pathways requiring targeted interventions.

Purpose of the Study:

• To review current understanding of asthma subtypes and their treatment implications.
• To identify research gaps and future directions in asthma management, particularly for T2 high and T2 low asthma.

Main Methods:

• Literature review of published studies, clinical guidelines, and trials.
• Analysis of data on biologic therapies for T2 high eosinophilic asthma.
• Identification of research needs for non-eosinophilic T2 low asthma.

Main Results:

• T2 high eosinophilic asthma, linked to IL-4, IL-5, and IL-13, has several biologic therapies.
• Efficacy and selection criteria for current biologics in T2 high asthma remain unclear.
• Non-eosinophilic T2 low asthma is under-researched with limited treatment options.

Conclusions:

• Personalized treatment strategies are essential for effective asthma management.
• Further head-to-head trials are needed to compare biologic efficacy in T2 high asthma.
• Research into T2 low asthma subtypes is crucial for developing new therapies.